AKT1 is altered in 1.02% of hematologic and lymphocytic disorder patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is altered in 0.13% of hematologic and lymphocytic disorder patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is altered in 0.88% of hematologic and lymphocytic disorder patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is altered in 0.3% of hematologic and lymphocytic disorder patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is altered in 2.32% of hematologic and lymphocytic disorder patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is altered in 1.02% of hematologic and lymphocytic disorder patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is altered in 0.89% of hematologic and lymphocytic disorder patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is altered in 0.69% of hematologic and lymphocytic disorder patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is altered in 1.11% of hematologic and lymphocytic disorder patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is altered in 0.73% of hematologic and lymphocytic disorder patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 2.02% of hematologic and lymphocytic disorder patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR is altered in 1.02% of hematologic and lymphocytic disorder patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is altered in 0.98% of hematologic and lymphocytic disorder patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC1 is altered in 0.85% of hematologic and lymphocytic disorder patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is altered in 1.96% of hematologic and lymphocytic disorder patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [3].